13 /PRNewswire-FirstCall/ -- Neurogen
Corporation today announced that it has commenced Phase I human testing of the Company's leading drug candidate for treatment of obesity.
Corporation (Branford, CT) has consummated its previously announced alliance with Merck & Co.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has completed the acquisition of Neurogen
Corporation (NASDAQ: NRGN), following approval of the transaction by Neurogen
stockholders earlier today.
Through the alliance, Neurogen
and Merck have generated a broad spectrum of chemical intellectual property and several leading drug candidates, including MK-2295.
Corporation (Branford, CT; 203-315-4615), a leading small molecule drug discovery and development company, and Aventis Pharma (Bridgewater, NJ; 908-231-4659), jointly announced an exclusive worldwide collaboration to develop new drugs for treatment of depression, anxiety, and other stress-related disorders based on Neurogen
's innovative portfolio of pre-clinical corticotrophin releasing factor (CRF1) antagonist compounds.
Stockholders Meeting to be held December 23, 2009
31 /PRNewswire-FirstCall/ -- Neurogen
Corporation , a drug discovery and development company, announced today that William H.
Under the new licensing agreement, Pfizer will develop GABA-based drug candidates identified by Neurogen
to treat anxiety and dementia in companion animals.
Corporation (NASDAQ: NRGN) announced today that it received a NASDAQ staff determination letter on December 11, 2009, notifying the company that it has not regained compliance, during a prescribed period, with NASDAQ Listing Rule 5450(a)(1), which requires the stock of listed companies to trade at or above $1.
30 /PRNewswire-FirstCall/ -- Neurogen
Corporation today announced that it has commenced a Phase II clinical trial in chronic insomnia patients with the Company's insomnia agent, NG2-73.
Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009.
26 /PRNewswire-FirstCall/ -- Neurogen
Corporation , a drug discovery and development company, announced today that it will release its third quarter 2006 financial results on Friday, November 3, 2006 before the opening of the U.